Investor Relations
News & Media
Positive Phase II Clinical Data
Collaboration partner announces Moscow IPO
Walbrook PR appointed by Lipoxen plc
Latest results on proprietary influenza vaccine
Lipoxen & Baxter agreement update
Result of Annual General Meeting 2010
AGM Correction of Date
Further PolyXen Technology Patent
Baxter Partnering Update
EMI share option and Joint Share Ownership awards
Notice of AGM
Director Dealing 27 May
Director Dealing 26 April
Director Dealing
Final Results for the year ended 31 December 2009
£1.2m Successful Placing
ErepoXen Phase II Trial Commences
European Patent Granted
Trading and Programme Update
Patent Granted
New Research Collaboration with Pharmsynthez
Lipoxen Additional listing
Additional listing and Total Voting Right
Senior Management Appointment
Lipoxen Appointed Lead for Vaccine Programme Grant
Interim Results for the six months ended 30 June 2009
Additional Listing
Director/PDMR Shareholding
Audit and Remuneration Committee Membership
Result of Annual General Meeting
Director Shareholding
Scott Maguire, CEO of Lipoxen, talks to Proactive Investors
Notice of Annual General Meeting
Lipoxen's Co-Delivery DNA Vaccine Patent Granted in EU and US
New Evaluation Agreement Signed with Major Pharma Company
Malaria Vaccine Agreements
Positive Data for Revolutionary Influenza Vaccine
Interim Phase I Results - Long Acting EPO
Lipoxen Signs Agreement with the Barbara Davis Center
Lipoxen to Investigate the Development of Long-Acting GCSF
Lipoxen to Develop Improved Delivery of Antiviral Drugs for the Treatment of Liver Disease caused by Hepatitis C
Lipoxen enters into agreement to develop improved vaccines
Lipoxen announces Board Changes
Lipoxen Chief Scientific Officer, Professor Gregory Gregoriadis, Awarded Two Lifetime Achievement Honours
Lipoxen to present at the SMi Drug Delivery Global Summit
Lipoxen Strengthens Management Team
Financial Results for the 12 months ended 31 December 2007
Canadian EPO Trial Correction
Lipoxen has received approval to conduct the second Phase I trial
Lipoxen receives grant to research improved HIV vaccine delivery
Lipoxen announces positive Phase I data with its long-acting insulin candidate, SuliXen
Lipoxen PLC Presenting at Sachs Associates
Lipoxen Announces Positive Phase I ErepoXen Results
Lipoxen reports further advancement of its DNA vaccine delivery patent portfolio
Lipoxen Completes Technology Transfer for Sustained-Release Insulin
Sachs conference
Lipoxen announces that its partner Serum Institute of India has begun Phase I trials of long-acting erythropoietin (EPO)
Lipoxen reports significant progress in the development of its DNA vaccine delivery patent portfolio
Change of Adviser
Lipoxen's first clinical candidate, SuliXen, enters Phase I trials
Lipoxen Signs Intervet Agreement
Lipoxen Announces $75M Agreement with Baxter to Develop New Blood Clotting Factors
Development and Manufacturing Agreement with the Serum Institute of India Limited
Lipoxen Receives Bio Entrepreneur of the Year Award
Preliminary Results for the Year Ended 31 December 2005
Lipoxen Announces Positive Data for its ImuXen ® Liposomal Technology
Lipoxen Plc lists on AIM raising £3.78million